Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Natl Med J India ; 26(4): 216-7, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24758445

RESUMO

Cryptococcosis is a common opportunistic systemic disease in immunocompromised patients. Pulmonary or brain cryptococcosis is the most common clinical presentation. Immunocompetent patients can also be affected, especially in tropical and subtropical zones where the life cycle of the causal agent, Cryptococcus gattii, is completed. We present a previously healthy man with progressive intracranial hypertension and a right paraventricular mass on CT scan and MRI. Cryptococcus gattii yeasts were isolated from the cerebrospinal fluid. A ventriculoperitoneal shunt was placed and the patient was treated with amphotericin B, fluconazole and dexamethasone. The patient died due to severe intracranial hypertension.


Assuntos
Cryptococcus gattii , Hipertensão Intracraniana/microbiologia , Meningite Criptocócica/diagnóstico , Adulto , Evolução Fatal , Humanos , Imunocompetência , Hipertensão Intracraniana/cirurgia , Imageamento por Ressonância Magnética , Masculino , Meningite Criptocócica/complicações , Meningite Criptocócica/tratamento farmacológico , Tomografia Computadorizada por Raios X , Derivação Ventriculoperitoneal
2.
Rev. Soc. Esp. Dolor ; 16(2): 87-96, mar. 2009. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-73812

RESUMO

Introducción: En la actualidad el estrés oxidativo, la neuro-inflamación y la activación glial han adquirido relevancia en la fisiopatología del síndrome doloroso regional complejo (SDRC), de ahí que la terapia con agentes antioxidantes e inhibidores de la producción decitocinas proinflamatorias ha comenzado a ensayarse. El Vimang® es una marca comercial registrada que cubre varios tipos de formulaciones a partir del extracto de la corteza delárbol de mango con efecto inhibidor de la activación del factor de transcripción nuclea rkB (NFkB), promotor de la expresión de mediadores y sistemas enzimáticos involucrados en la inflamación y el dolor, el estrés oxidativo y la plasticidad sináptica. Objetivo: El propósito del presente estudio fue determinar la actividad analgésica de la suplementación con formulaciones Vimang® en 15 pacientes con SDRC y la posible mejoría de la capacidad funcional postratamiento. Material y métodos: Los pacientes recibieron Vimang® tabletas 1.800 mg/día/8 h, crema1,2% en el miembro afectado 3 veces/día y un bloqueo simpático semanal durante 4meses. Se introdujo la fisioterapia al mes. Las variables evaluadas fueron las puntuaciones diarias medias de dolor (PDMD) mediante una escala de Likert, el área e intensidad de la alodinia mecánica dinámica, la alodinia al frío, somática profunda y la frecuencia del dolor paroxístico. Se aplicó la escala de Enneking et al. modificada para evaluar la funcionabilidad articular. Resultados: Las PDMD y el resto de las alteraciones sensoriales se redujeron significativamente desde la semana 2 a 3 de iniciado el tratamiento respecto a los valores iniciales.La funcionabilidad del miembro afectado aumentó de un promedio de 22,7 a 78,7%. Estas formulaciones pudieran introducirse en el tratamiento del SDRC, pero es necesario sistematizarlos estudios (AU)


Introduction: Currently, oxidative stress, neuroinflammation and glial activation are accepted as playing a pathophysiological role in complex regional pain syndrome (CRPS)and consequently antioxidant agents and proinflammatory cytokine inhibitors have begun to be assessed in the treatment of this disorder. Vimang® is a new phyto drug prepared from the stem bark of Mangifera indica L., registered in Cuba with inhibitory effect on nuclear transcription factor kB (NFkB), which induces expression of some mediators andenzymes involved in inflammation, oxidative stress, pain, and synaptic plasticity. Objective: To determine the analgesic effects of Vimang® tablets and 1.2% cream as atopical agent in 15 patients with CRPS, as well as possible improvement in post-treatment functional capacity. Material and methods: The patients received a daily dose of 1800 mg of Vimang® tablets for 120 days, 1.2% cream in the affected limb 3 times/day, and sympathetic blocks once a week for 4 months. Physiotherapy was introduced after 30 days. The variables evaluated were changes in average daily pain score through a Likert scale, the area and rate of dynamic mechanical allodynia, rate of cold allodynia, deep somatic allodynia and frequency of burning spontaneous pain. A modified scale of Enneking et al. was applied to evaluate functional capacity. Results: The average daily pain score and sensory abnormalities significantly improved from week 2-3. On average, the functional capacity of the affected limb increased from22.7 % to 78.7%. Our results suggest that Vimang® formulations might be useful in CRPS treatment. However, further studies are required (AU)


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Síndromes da Dor Regional Complexa/terapia , Analgesia/instrumentação , Síndromes da Dor Regional Complexa/fisiopatologia , Consentimento Livre e Esclarecido , Modalidades de Fisioterapia
3.
Nefrologia ; 29(1): 30-4, 2009.
Artigo em Espanhol | MEDLINE | ID: mdl-19240769

RESUMO

INTRODUCTION: Renal length estimation by ultrasound is an important parameter in clinical evaluation of kidney disease and healthy donors. Changes in renal volume may be a sign of kidney disease. Correct interpretation of renal length requires the knowledge of normal limits, these have not been described for Latin American population. OBJECTIVE: To describe normal renal length (RL) by ultrasonography in a group of Mexican adults. METHODS: Ultrasound measure of RL in 153 healthy Mexican adults stratified by age. Describe the association of RL to several anthropometric variables. RESULTS: A total of 77 males and 76 females were scanner. The average age for the group was 44.12 +/- 15.44 years. The mean weight, body mass index (BMI) and height were 68.87 +/- 11.69 Kg, 26.77 +/- 3.82 kg/m2 and 160 +/- 8.62 cm respectively. Dividing the population by gender, showed a height of 166 +/- 6.15 cm for males and 154.7 +/- 5.97 cm for females (p =0.000). Left renal length (LRL) in the whole group was 105.8 +/- 7.56 mm and right renal length (RRL) was 104.3 +/- 6.45 mm (p = 0.000.) The LRL for males was 107.16 +/- 6.97 mm and for females was 104.6 +/- 7.96 mm. The average RRL for males was 105.74 +/- 5.74 mm and for females 102.99 +/- 6.85 mm (p = 0.008.) We noted that RL decreased with age and the rate of decline accelerates alter 60 years of age. Both lengths correlated significantly and positively with weight, BMI and height. CONCLUSIONS: The RL was significantly larger in males than in females in both kidneys (p = 0.036) in this Mexican population. Renal length declines after 60 years of age and specially after 70 years.


Assuntos
Rim/anatomia & histologia , Rim/diagnóstico por imagem , Adulto , Idoso , Feminino , Humanos , Masculino , México , Pessoa de Meia-Idade , Tamanho do Órgão , Estudos Prospectivos , Valores de Referência , Ultrassonografia , Adulto Jovem
4.
Nefrología (Madr.) ; 29(1): 30-34, ene.-feb. 2009. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-104340

RESUMO

Introducción: la estimación del tamaño renal por ultrasonografía es un parámetro importante en la evaluación clínica y en el manejo de pacientes adultos con enfermedad renal y adultos sanos donadores. El cambio en el tamaño renal puede ser una evidencia muy sugerente de enfermedad, por lo que su interpretación requiere de parámetros específicos para la población a estudiar. En el caso de América Latina, no se han descrito parámetros normales. Objetivo: describir parámetros normales de Longitud Renal (LR) por ultrasonografía en una población mexicana adulta. Métodos: medición ultrasonográfica de LR en 153 adultos sanos estratificados por edad. Se investigó la posible asociación de la LR con parámetros antropométricos. Resultados: se estudiaron 77varones y 76 mujeres; la edad promedio fue de 44,12 ± 15,44años. El promedio de peso, Índice de Masa Corporal (IMC) y talla fue de 68,87 ± 11,69 kg, 26,77 ± 3,82 kg/m2y 160 ± 8,62cm, respectivamente. Al dividir a la población estudiada por género, encontramos que la talla fue de 166 ± 6,15 cm para varones y 154,7 ± 5,97 cm para mujeres, (p = 0,00). La Longitud Renal Izquierda (LRI) en el grupo total fue de 105,8 ±7,56 mm, y la Longitud Renal Derecha (LRD), de 104,3 ± 6,45mm (p = 0,000). La LRI en varones fue de 107,16 ± 6,97 mm, y en mujeres, de 104,6 ± 7,96 mm. La media de la LRD en varones fue de 105,74 ± 5,74 mm y en mujeres, de 102,99 ±6,85 mm, (p = 0,008). La LR disminuyó con la edad, y la tasa de disminución parece aumentar después de los 60 años. Las LR se correlacionaron de forma significativa y positiva con el peso, el IMC y la talla. Conclusiones: la LR fue significativamente mayor en varones que en mujeres para ambos riñones (p = 0,036). La LR disminuyó continuamente con la edad, especialmente después de los 60 años y de forma significativa después de los 70 años (AU)


Introduction: Renal length estimation by ultrasound is an important parameter in clinical evaluation of kidney disease and healthy donors. Changes in renal volume may be a sign of kidney disease. Correct interpretation of renal length requires the knowledge of normal limits, these have not been described for Latin American population. Objective: To describe normal renal length (RL) by ultrasonography in a group of Mexican adults. Methods: Ultrasound measure of RL in 153 healthy Mexican adults stratified by age. Describe the association of RL to several anthropometric variables. Results: A total of 77 males and 76 females were scanner. The average age for the group was 44.12 ± 15.44 years. The mean weight, body mass index (BMI) and height were 68.87 ± 11.69 Kg, 26.77 ± 3.82 kg/m2 and 160 ± 8.62 cm respectively. Dividing the population by gender, showed a height of 166 ± 6.15 cm for males and 154.7 ± 5.97 cm for females (p =0.00). Left renal length (LRL) in the whole group was 105.8 ± 7.56 mm and right renal length (RRL) was 104.3 ± 6.45 mm (p = 0.000). The LRL for males was 107.16 ± 6.97 mm and for females was 104.6 ± 7.96 mm. The average RRL for males was 105.74 ± 5.74 mm and for females 102.99 ± 6.85 mm (p = 0.008). We noted that RL decreased with age and the rate of decline accelerates alter 60 years of age. Both lengths correlated significantly and positively with weight, BMI and height. Conclusions: The RL was significantly larger in males than in females in both kidneys (p = 0.036) in this Mexican population. Renal length declines after 60 years of age and specially after 70 years (AU)


Assuntos
Humanos , Rim/anatomia & histologia , Tamanho do Órgão , Ultrassonografia/métodos , México , Fatores Etários , Valores de Referência
5.
Rev. Soc. Esp. Dolor ; 14(7): 494-500, sept. 2007. ilus
Artigo em Es | IBECS | ID: ibc-64023

RESUMO

Los avances en el conocimiento actual de la fisiopatología del Síndrome Doloroso Regional Complejo (SDRC), conducen a la búsqueda de nuevos fármacos dirigidos a los blancos moleculares que se involucran en sus complejos mecanismos. En la actualidad se considera el papel activo de la neuroinflamación en el fenómeno de hiperexcitabilidad del cuerno dorsal espinal y el establecimiento de la sensibilización central dentro de sus procesos subyacentes. El Extracto obtenido de la corteza de variedades seleccionadas de la especie Mangifera indica L. y que se comercializa en Cuba bajo la Marca Registrada VIMANG®, posee actividad antioxidante, antiinflamatoria y antihiperalgésica in vivo. Por otra parte estudios in vitro demostraron su efecto inhibidor sobre múltiples moléculas que participan en la cascada de la sensibilización central y en un modelo de isquemia-reperfusión sus cualidades neuroprotectoras. Presentamos el caso de una paciente con diagnóstico de SDRC tipo II, secundario a una lesión del plexo braquial, con sección del nervio radial a nivel humeral que fue provocada por el desplazamiento de la fractura del húmero izquierdo. La paciente llega a nuestro servicio a los 4 meses de evolución, con síntomas sensoriales, dolor persistente quemante y paroxístico, alodinia mecánica, edema, cambios vasomotores hacia la hiperhemia y mano en flexión por pérdida de la función motora de los músculos extensores del antebrazo. Con compromiso de la articulación del carpo y hombro de limitación severa y dolor de valor 5 en una escala numérica de Likert. El estudio de conducción nerviosa mostró alteraciones mielínico-axonales discretas del nervio mediano y mielínico-axonales severas del nervio radial. Se instauró el tratamiento con Vimang (300mg) 2 tabletas cada 8 horas por 4 meses y la aplicación local de la crema Vimang 3 veces al día, asociado a los bloqueos simpáticos y somáticos para miembro superior y a la fisioterapia. La evolución clínica y electrofisiológica fue muy favorable. Este caso constituye el primero descrito en la literatura, en el cual se introduce este producto a la terapia múltiple del síndrome, se deben dirigir los estudios básicos y clínicos en este sentido, dadas las posibilidades terapéuticas del Vimang® en el SDRC (AU)


Advances in our understanding of Complex Regional Pain Syndrome (CRPS) physiopathology have led to new drugs targeted toward molecular mediators involved in the complex mechanisms of pain. Neuroinflammation is thought to have an active role in phenomena underlying spinal cord dorsal horn hyperexcitability and the establishment of central sensitivity. An extract from the bark of selected Mangifera indica L species, registered under the Vimang® Trade Mark in Cuba, has antioxidant, anti-inflammatory and antihyperanalgesic activity in vivo. In Vitro studies have demonstrated that it has an inhibitory effect on several molecules mediating the central sensitization cascade and an ischemic-reperfusion model has proved its cerebral neuroprotective qualities. We present a patient with type II CRPS secondary to a brachial plexus lesión following a displaced left humerus fracture that sectioned the radius nerve. The patient presented in our pain clinic four months after the accident with sensorial symptoms, persistent burning pain mechanical allodynia, oedema, vasomotor alterations tending to hyperhaemia and a flexed hand due to loss of the motor function in the fore arm extensors. Carpal and shoulder Joint movement was severely limited and she scored 5 on the Likert pain scale. Electrophysiological study revealed mild myelin-axonal alterations in the median nerve and severe alterations in the radial nerve. Treatment with Vimang (300 mg; 2 tablets/8 hours/4 months) with topical administration of Vimang cream 3 times per day combined with sympathetic and somatic nerve blocks in the upper limb and physiotherapy were begun. The patient's clinical and electrophysiological evolution was very favourable. This is the first description of the use of this product in combined CRPS therapy. Our results indicate that further basic and clinical research into the use of Vimang® for CRPS is Justified (AU)


Assuntos
Humanos , Mangifera/farmacologia , Síndromes da Dor Regional Complexa/tratamento farmacológico , Mangifera/administração & dosagem , Síndromes da Dor Regional Complexa/diagnóstico
6.
Rev. Soc. Esp. Dolor ; 14(4): 296-306, mayo 2007. ilus
Artigo em Es | IBECS | ID: ibc-64003

RESUMO

Los modelos animales de dolor han permitido en las últimas décadas un salto en las investigaciones de su neurobiología, pero los sistemas biológicos no son exactos y haymúltiples factores que pueden determinar resultados contradictorios. Las dificultades se exacerban al diseñar modelos en los que se aplique la electroacupuntura, pues existe una variabilidad paramétrica para la liberación de mediadores, tambiénpara la respuesta de los sistemas bioquímicos manipulados en condiciones fisiológicas o patológicas, marcadainfluencia de la Analgesia Inducida por Estrés (SIA), entreotras. Nuestro propósito es analizar críticamente algunos experimentos recientes en este campo, de autores que han enfrentado estas dificultades y aún así, han aportado elementosimportantes para el esclarecimiento de los mecanismos involucradosen la analgesia acupuntural (AU)


Animal models of pain have permitted in the last decadesimportant advances in neurobiologic research, but biologicalsystems are not exact and there are multiple factors that canlead to contradictory results. Those difficulties are exacerbatedin models addressed to electroacupuncture treatment procedures,as a parametric variability exists for the liberation of mediators, also for the response of biochemical systems manipulatedunder physiologic or pathological conditions, amongother the influence of the stress induced analgesia (SIA). Ourpurpose is to critically analyze some recent experiments in thisfield, from authors that have faced these difficulties and stillhave provided important elements for the clarification of themechanisms involved in acupuncture analgesia (AU)


Assuntos
Animais , Ratos , Eletroacupuntura/métodos , Dor/terapia , Nociceptores/fisiopatologia , Modelos Animais , Carragenina/uso terapêutico , Ketamina/uso terapêutico , Depressão Sináptica de Longo Prazo
7.
Oncología (Barc.) ; 23(9): 417-421, sept. 2000. tab, graf
Artigo em Es | IBECS | ID: ibc-10355

RESUMO

El Cis-Platino (CP), antitumoral ampliamente utilizado en oncología, posee una marcada nefrotoxicidad. En el presente trabajo se determina la influencia del pretratamiento, con Subcitrato de Bismuto Coloidal (SBC), a dosis de 100, 500 y 1000 mg/kg, sobre la nefrotoxicidad y actividad antitumoral del CP (5 y 10 mg/kg) en ratones B602F-1 previamente transplantados con leucemia p 388. La actividad antitumoral se evaluó mediante la sobrevida promedio y el índice de aumento de sobrevida. Como indicador del daño renal se midieron los niveles plasmáticos de urea y se analizaron histológicamente los riñones. Los resultados evidenciaron que el pretratamiento con SBC no afectó la actividad antitumoral del CP disminuyendo la nefrotoxicidad inherente al mismo al revertir a la normalidad los valores plasmáticos de urea y atenuando el daño a nivel histológico (AU)


Assuntos
Animais , Camundongos , Cisplatino/uso terapêutico , Cisplatino/toxicidade , Cisplatino/efeitos adversos , Bismuto/uso terapêutico , Bismuto/administração & dosagem , Proteínas Oncogênicas/administração & dosagem , Ensaios de Seleção de Medicamentos Antitumorais , Rim , Rim/lesões
8.
Neuroimmunomodulation ; 6(3): 187-92, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10213917

RESUMO

The neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) reduces fever and acute inflammation in the skin when administered centrally. The aim of the present research was to determine whether central alpha-MSH can also reduce signs of systemic inflammation in mice with endotoxemia. Increases in serum tumor necrosis factor-alpha and nitric oxide, induced by intraperitoneal administration of endotoxin, were modulated by central injection of a small concentration of alpha-MSH. Inducible nitric oxide synthase (iNOS) activity and iNOS mRNA in lungs and liver were likewise modulated by central alpha-MSH. Lung myeloperoxidase activity, a marker of neutrophil infiltration, was increased in endotoxemic mice; the increase was significantly less in lungs of mice treated with central alpha-MSH. Intraperitoneal administration of the small dose of alpha-MSH that was effective centrally did not alter any of the markers of inflammation. In experiments using immunoneutralization of central alpha-MSH, we tested the idea that endogenous peptide induced within the brain during systemic inflammation modulates host responses to endotoxic challenge in peripheral tissues. The data showed that proinflammatory agents induced by endotoxin in the circulation, lungs, and liver were significantly greater after blockade of central alpha-MSH. The results suggest that anti-inflammatory influences of neural origin that are triggered by alpha-MSH could be used to treat systemic inflammation.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Endotoxemia/tratamento farmacológico , Inflamação/prevenção & controle , Neuroimunomodulação/efeitos dos fármacos , alfa-MSH/uso terapêutico , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/farmacologia , Endotoxemia/sangue , Endotoxemia/complicações , Indução Enzimática , Febre/etiologia , Febre/prevenção & controle , Inflamação/etiologia , Inflamação/fisiopatologia , Injeções Intraperitoneais , Injeções Intraventriculares , Fígado/enzimologia , Pulmão/enzimologia , Masculino , Camundongos , Nitratos/sangue , Óxido Nítrico/análise , Óxido Nítrico Sintase/biossíntese , Óxido Nítrico Sintase Tipo II , Nitritos/sangue , Peroxidase/sangue , Choque Séptico/sangue , Choque Séptico/complicações , Choque Séptico/prevenção & controle , Fator de Necrose Tumoral alfa/análise , alfa-MSH/administração & dosagem , alfa-MSH/farmacologia
9.
Eur J Pharmacol ; 317(2-3): 369-76, 1996 Dec 19.
Artigo em Inglês | MEDLINE | ID: mdl-8997623

RESUMO

In previous work, we reported that chlorpromazine inhibits tumor necrosis factor (TNF) production in endotoxin lipopolysaccharide-treated mice, and protects against lipopolysaccharide toxicity. Chlorpromazine is used as an antipsychotic and has several effects on the central nervous system. It acts on different neurotransmitter receptors and has other biochemical activities some of which, like inhibition of phospholipase A2, might be responsible for the inhibitory effect on TNF production. To investigate the role of these actions in the inhibition of TNF production by chlorpromazine, we have synthesized some chlorpromazine derivatives that do not have central activities. Some of these analogs have lost their affinity for various receptors and their phospholipase A2 inhibitory activity, but still inhibit TNF production. No correlation was found between TNF inhibition and the ability to inhibit nitric oxide (NO) synthase, whereas a good correlation was evident between TNF inhibition and antioxidant activity.


Assuntos
Antioxidantes/farmacologia , Clorpromazina/análogos & derivados , Clorpromazina/farmacologia , Fator de Necrose Tumoral alfa/biossíntese , Animais , Pressão Sanguínea/efeitos dos fármacos , Depressão Química , Inibidores Enzimáticos/farmacologia , Técnicas In Vitro , Lipopolissacarídeos/farmacologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Atividade Motora/efeitos dos fármacos , Óxido Nítrico Sintase/antagonistas & inibidores , Fosfolipases A/antagonistas & inibidores , Fosfolipases A2 , Ratos , Ratos Wistar , Receptores de Neurotransmissores/efeitos dos fármacos , Receptores de Neurotransmissores/metabolismo , Suínos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...